Literature DB >> 30904268

Building a tuberculosis-free world on a foundation of universal health coverage.

Ban Ki-Moon1.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30904268     DOI： 10.1016/S0140-6736(19)30433-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Evaluation of the first level of care for tuberculosis control in Buenos Aires, Argentina.

Authors:  Javier Mariani; Daniel Ferrante; Gabriel Battistella; Martín Langsam; Freddy Pérez; Alejandro Macchia
Journal:  Rev Panam Salud Publica       Date:  2021-02-05

2.  [Evaluation of the first level of care for tuberculosis control in Buenos Aires, ArgentinaAvaliação da atenção primária à saúde no controle da tuberculose em Buenos Aires, Argentina].

Authors:  Javier Mariani; Daniel Ferrante; Gabriel Battistella; Martín Langsam; Freddy Pérez; Alejandro Macchia
Journal:  Rev Panam Salud Publica       Date:  2020-12-14

3.  Evaluation of the 2016-2020 regional tuberculosis response framework, WHO Western Pacific Region.

Authors:  Kerri Viney; Chris Lowbridge; Fukushi Morishita; Kalpeshsinh Rahevar; Kyung H Oh; Tauhid Islam; Ben J Marais
Journal:  Bull World Health Organ       Date:  2021-03-02       Impact factor: 9.408

4.  A Retrospective Comparative Study on Median Time to Sputum Culture Conversion in Multi-Drug Resistant Pulmonary Tuberculosis Patients in Pastoral and Non-Pastoral Settings in Southeast Oromia, Ethiopia.

Authors:  Abebe Megerso; Negusie Deyessa; Godana Jarso; Alemayehu Worku
Journal:  Infect Drug Resist       Date:  2021-12-14       Impact factor: 4.003

5.  Electronic pillbox-enabled self-administered therapy versus standard directly observed therapy for tuberculosis medication adherence and treatment outcomes in Ethiopia (SELFTB): protocol for a multicenter randomized controlled trial.

Authors:  Tsegahun Manyazewal; Yimtubezinash Woldeamanuel; David P Holland; Abebaw Fekadu; Henry M Blumberg; Vincent C Marconi
Journal:  Trials       Date:  2020-05-05       Impact factor: 2.279
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.